Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Basal Health vs NuuVim

Basal Health
Graded #494

Lower grade

vs+20.5
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 47.7/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +43
45
88
Dose & formulationNuuVim +56
40
96
Clinical oversightBasal Health +6
48
42
Labs & monitoringEven
50
50
FulfillmentNuuVim +3
58
61
Contract termsBasal Health +8
55
47
Basal Health · left barNuuVim · right bar

The numbers

MetricBasal HealthNuuVim
WeighScore47.7/10068.2/100
GradeCC
Scorecard rank#494#153
SemaglutideNot disclosed$79/mo (all doses, 3-mo plan, new patients only, compounded)
TirzepatideNot disclosed$133/mo (all doses, 3-mo plan, new patients only, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard